Contipharma SA
1.3 FTEThe score of Contipharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +33 % Total assets +36 % Headcount (avg FTE) +30 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Contipharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 14 Oct 2026
- Year ended 31 Dec 2024filed on 01 Aug 2025
- Year ended 31 Dec 2023filed on 27 Sep 2024
- Year ended 31 Dec 2022filed on 10 Jul 2023
- Year ended 31 Dec 2021filed on 20 Jul 2022
Contipharma's financial analysis
- Solvency44.8%sector median: 44.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Contipharma
Contipharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0466.820.220
- VAT number
- BE0466820220
- Peppol
- Registered · 0208:0466820220 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 09 Sep 1999
- Registered office
- 4100 Seraing
- Size
- Micro · 1.3 FTE
- Latest accounts
- 2025 · filed on 14 Oct 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Contipharma (SA) has been based in Seraing since 1999, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of €1.07m and equity of €3.23m; its revenue is not published. With 1.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 44.8%, above the median of its sector (44.7%).
Companies similar to Contipharma
Companies in the same business, of comparable size and area, outside its group.
- RNA Pioneering Business and other management consultancy activities Ghent · balance sheet €5.63m
- Motion Medical Holding Manufacture of medical and dental instruments and supplies Les Bons Villers · balance sheet €4.44m
- DYSS Retail sale of pharmaceutical products Scherpenheuvel-Zichem · balance sheet €6.77m
- Chaflo Retail sale of pharmaceutical products Dendermonde · balance sheet €6.17m
- Credophar Wholesale of pharmaceutical and medical goods Ghent · balance sheet €7.84m
- Aagato Medical Wholesale of pharmaceutical and medical goods Ghent · balance sheet €3.86m
- Corpowell Wholesale of pharmaceutical and medical goods Antwerp · balance sheet €3.37m
- Covarmed Wholesale of pharmaceutical and medical goods Kortrijk · balance sheet €4.93m
Frequently asked questions about Contipharma
What is the revenue of Contipharma?
Contipharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Contipharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0466820220 for Contipharma, if the company is VAT-registered. Its company number (CBE) is 0466.820.220.
Where is the registered office of Contipharma?
According to the CBE register, the registered office of Contipharma is in 4100 Seraing.
What is the equity of Contipharma?
At the close of the 2025 financial year, the equity of Contipharma amounts to 3,234,545 €, a solvency of 44.8% of total assets.
How many people work at Contipharma?
1.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Contipharma?
The register lists 2 active mandates at Contipharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Contipharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →